Anjana Narain, who has previously held positions in pharmaceutical leaders including GSK, Merck, and Bayer, was appointed by CSL as the EVP and general manager of its Seqirus business.
Narain will fill the position after the retirement of Gordon Naylor, which was announced earlier this year.
CSL CEO, Paul Perreault commented that Narain will bring a ‘diverse, broad-based’ experience to Seqirus, the influenza vaccines business that CSL acquired from Novartis in 2015.
"As a global leader in influenza prevention, Seqirus is well positioned to deliver sustainable growth," commented Narain.
The executive spent nine years leading influenza commercialization business, vaccine and HIV management at GSK, while previously she had held leadership roles in the biopharmaceutical and vaccines business at Merck and Bayer.